Chronic Kidney Disease Burden Across EU/EEA Countries: Structural Determinants, Mortality Convergence and Comparison of Global Burden of Disease Estimates with Vital Registration Data
Oct 2026· Epidemiologia· Vol 7, pp. 152· 0 citations· 30 references
TL;DR
The structural determinants examined did not explain cross-country differences in GBD-estimated CKD burden, and no consistent regional pattern emerged, and GBD-derived estimates alone are insufficient to infer diagnostic inequality between countries.
Abstract
Background and Objectives: Cross-country differences in chronic kidney disease (CKD) burden across Europe, as estimated by the Global Burden of Disease (GBD) study, are often interpreted as reflecting unequal diagnosis, yet this interpretation has rarely been examined against other data sources. This study examined associations between economic, social and environmental determinants and CKD prevalence and mortality across 29 European Union and European Economic Area countries, assessed convergence between 1990 and 2023, and compared GBD estimates with vital registration data. Materials and Methods: Age-standardized CKD prevalence, mortality and disability-adjusted life years were obtained from GBD 2023. Cross-sectional regression (2023; heteroskedasticity-consistent standard errors; n = 27), k-means cluster analysis, and sigma- and beta-convergence analyses were performed. GBD mortality was compared with Eurostat death rates for diseases of the kidney and ureter (ICD-10 N00–N29, 2011–2023). GBD input sources for CKD prevalence were reviewed for Estonia, Latvia, Lithuania and Austria. Results: No structural determinant was robustly associated with CKD prevalence or mortality, and outcomes did not differ significantly across the three-cluster typology (Kruskal–Wallis, p = 0.17–0.75). Mortality dispersion declined between the mid-1990s and the mid-2000s and stagnated thereafter. Prevalence dispersion increased marginally until the mid-2000s, with no significant trend from 2008 onward. Rank agreement between GBD and Eurostat mortality was moderate (ρ = 0.38 in 2023, down from 0.61 in 2017) and improved when diabetes deaths were added (ρ = 0.66). Estonia showed the largest discrepancy. Prevalence estimates for all four reviewed countries relied mainly on kidney replacement therapy registries, and no population-based source was identified for Latvia or Lithuania. Conclusions: The structural determinants examined did not explain cross-country differences in GBD-estimated CKD burden, and no consistent regional pattern emerged. Part of this variation is compatible with differences in cause-of-death coding and sparse local input data. GBD-derived estimates alone are therefore insufficient to infer diagnostic inequality between countries, and direct indicators of screening and detection are needed.
BACKGROUND
Global chronic kidney disease (CKD) burden from metabolic risks has risen steadily. Using 2021 Global Burden of Disease (GBD) data, this study examines 1990-2021 spatiotemporal trends and regional disparities in CKD to inform prevention.
METHODS
We analyzed 1990-2021 GBD data on metabolic-related CKD burde...
Ke-Rong Jiang, Li-Min Yin, Yong-Sheng Pan et al.· Journal of the National Medi...· 1 citation
Background & Objective: High fasting plasma glucose (HFPG) is a major modifiable metabolic risk factor for cardiovascular disease, chronic kidney disease, premature mortality, and disability. South Asia faces a growing cardiometabolic burden, yet long-term country-level trends, inequalities, and future HFPG-attributabl...
Muhammad Shoaib Khan, Suleman Khan, Safia Wazir et al.· Journal of Saidu Medical Col...· 0 citations
Importance
Heart failure (HF) is a common condition with substantial geographical variation in its prevalence and underlying etiologies. Consistent and comparable data on the burden of HF within populations are needed to inform health system priorities.
Objective
To estimate the global burden of HF.
Design, Setting...
Catherine O. Johnson, Madineh Abbasi, M. Abbasifard et al.· JAMA cardiology· 2 citations
Overall, economic development alone may be insufficient to reduce CKD prevalence, highlighting the importance of health investment and risk-factor management.
Yi-Ting Hu· Advances in Management and A...· 0 citations
Differentiated prevention and control strategies targeting low SDI regions, with attention to gender and older population differences, are needed to address key risk factors and reduce health inequalities.
Yu Sun, Shu Li, Dan Xu et al.· Tobacco Induced Diseases· 0 citations
Background and Aims: Cardiovascular disease (CVD) remains the leading cause of global mortality. We evaluated 24 year global trends in age-standardized CVD mortality across 204 countries and territories (2000-2023) and decomposed the independent longitudinal associations of major cardiometabolic risk factor pathways. M...
K. M. Al-Dhayani· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.